C 4
X D

C4X Discovery Holdings Limited

Board Change

David Lawrence appointed as Interim Chairman; Clive Dix to retire from leading the Company

2 January 2025 - C4X Discovery Holdings Limited ("C4XD"), the immuno-inflammation therapeutics company, today announces that Executive Chairman, Clive Dix, has decided to step down after 10 years of service. David Lawrence has joined the Board of Directors as an independent Non-Executive Director and has been appointed as Interim Non-Executive Chairman with immediate effect until a permanent CEO and Chairman is in place.

During Clive's tenure, C4XD has focused on building a robust immuno-inflammatory portfolio, underpinned by its unique PatientSeek genetic insights platform. The business has secured multiple agreements, including licensing deals, with leading pharmaceutical partners. Clive has overseen a growing pipeline, with a lead oral a4b7 integrin inhibitor programme in inflammatory bowel disease, and progress being made with C4XD's oral PAD4 inhibitor for rheumatoid arthritis.

Clive Dix, Executive Chairman of C4XD, said: *"C4XD has been an inspirational place to work, with exceptional science and people at its heart, and I could not be more proud of the Company we have built. I thank the team at C4XD for a wonderful 10 years and I wish them every success for the future. I am delighted that David Lawrence, an industry veteran, will be leading the Company until a permanent successor is appointed. David will work with our management team to continue to execute the development programmes and collaborate with our partners.*

"David joins C4XD with a strong track record in both publicly listed and private companies. He has overseen multiple fundraisings spanning early investors, VCs and public markets across US, UK and Europe, as well as more than 100 transactions. With David at the helm, I know C4XD will be in experienced hands as it moves to the next stage of its journey."

David Lawrence, incoming Interim Chairman of C4XD added: *"As the incoming interim Chairman, I want to thank Clive for his incredible work and commitment during his tenure. The impact of his expertise cannot be overstated, having built C4XD from a pioneering drug discovery company into an exciting and innovative immuno-inflammatory therapeutics company. Under Clive's leadership, C4XD has built a pipeline of encouraging immuno-inflammatory candidates and has secured impressive deals with leading pharmaceuticals companies. I am honoured to be taking the reins and look forward to working with the team."*

David is currently a Non-Executive Director at EnteroBiotix, a UK private, clinical-stage microbiome company, and Glen Clova Scientific, a UK private biotech creating a new class of active biologics. He began his career at GSK and has held senior and executive roles at leading companies such as Chiron Vaccines which was acquired by Novartis and Acambis which was acquired by Sanofi and Valneva, where he led its US IPO. David also co-founded Synpromics, a synthetic biology company, where he recruited the senior management team and the Board; Synpromics was acquired by Ask Bio in 2019.

Contacts

C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977

C4X Discovery Media – ICR Healthcare (Europe)
Mary-Jane Elliott, Angela Gray, Lucy Featherstone +44 (0)203 709 5700

C 4
X D

Notes to Editors:

About C4X Discovery
C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world-leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. We are advancing our internal portfolio which ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have two commercially partnered programmes with Sanofi and AstraZeneca, and one clinical stage candidate which has been acquired by Indivior.

For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.